REN and metastatic colorectal cancer: The retrospective analysis of clinical data from metastatic colorectal cancer patients who received renin–angiotensin system inhibitors (RASIs) during combined anti-angiogenic and chemotherapeutic treatment showed significant survival benefits of overall survival and progression-free survival over patients who did not receive RASIs.